摘要
Dear Editor,I am Dr.Daniel Russell Richardson from the West Virginia University Eye Institute in Morgantown,West Virginia,United States.I write to present a case of uveitis associated with nivolumab,which is a promising new immune checkpoint inhibitor（ICI）for metastatic melanoma and non-small cell lung carcinoma with expanding indications.As the use of nivolumab continues to increase,ophthalmologists must be aware of uveitis as an adverse event.
Dear Editor,I am Dr.Daniel Russell Richardson from the West Virginia University Eye Institute in Morgantown,West Virginia,United States.I write to present a case of uveitis associated with nivolumab,which is a promising new immune checkpoint inhibitor（ICI）for metastatic melanoma and non-small cell lung carcinoma with expanding indications.As the use of nivolumab continues to increase,ophthalmologists must be aware of uveitis as an adverse event.
